Oncopeptides AB (publ) (ONCO.ST) — Stock Score Summary

Oncopeptides AB (publ) (ONCO.ST) has a MoatMap StockRank of 6/100 based on Quality (27/100), Value (45/100), and Momentum (11/100) factor scores. The current signal is STRONG SELL. Oncopeptides is a small-cap Swedish biotech focused on oncology that lacks the scale, commercialized portfolio, or CDMO pricing power required to fit our high-conviction healthcare themes.

Oncopeptides AB (publ) is a commercial-stage biotech company specializing in targeted therapies for difficult-to-treat hematological diseases, with its lead product Pepaxti approved in Europe for multiple myeloma. The company's competitive moat is anchored in its proprietary Peptide-Drug Conjugate (PDC) platform, which rapidly delivers cytotoxic agents directly into cancer cells. It operates as a specialized oncology player focused on commercializing its platform in European and global markets.

Key Financial Metrics

Price$0.19
Market Cap$76M
P/E (Forward)-2.46
Price/Book-8.09
Return on Equity-623.3%
Return on Invested Capital-258.7%
Debt/Equity170.35
Gross Margin96.6%
Operating Margin-147.9%
Revenue Growth91.3%
Free Cash Flow$-1M

Oncopeptides AB (publ) operates in the Biotechnology industry, part of the Healthcare sector (Sweden).

Frequently Asked Questions

What is Oncopeptides AB (publ)’s (ONCO.ST) StockRank?
MoatMap’s StockRank for Oncopeptides AB (publ) (ONCO.ST) is 6/100, with a Strong Sell signal. It is a composite of Quality (27), Value (45), and Momentum (11) factor ranks across MoatMap’s 19,000+ stock universe.
Does Oncopeptides AB (publ) have an economic moat?
Oncopeptides AB (publ) (ONCO.ST) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Oncopeptides AB (publ) a buy, hold, or sell?
MoatMap’s current signal for Oncopeptides AB (publ) (ONCO.ST) is Strong Sell, based on a StockRank of 6/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Oncopeptides AB (publ) in?
Oncopeptides AB (publ) (ONCO.ST) operates in the Healthcare sector, specifically the Biotechnology industry (Sweden).
Browse all ranked stocksONCO.ST deep dive reportAI ChampionsHow we score stocksSense-check another stock